Table 1

Progression of trial

Period	Screening	Active treatment									F/U
Visit	Screening	1	2	3	4	5	6	7	8	9*	10
Week	0	1		2		3		4			12
Consent	†
Demographic survey	†
Medical history	†	‡	‡	‡	‡	‡	‡	‡	‡	†	†
Vital signs	†	‡	‡	‡	‡	‡	‡	‡	‡		†
Physical examination	†
Conformity assessment	†
Check PSA	†
Check prostate size (TRUS)	†
Inclusion/exclusion criteria	†
Inform patient of the visit schedule	†	‡	‡	‡	‡	‡	‡	‡	‡	‡
Randomisation	†
Moxibustion	†	‡	‡	‡	‡	‡	‡	‡	‡
IPSS	†					‡				†	†
SF-36	†					‡				†	†
PGIC			‡	‡	‡	‡	‡	‡	‡	†	†
Qmax	†										†
PVR	†										†
FVC	†										†
Adverse event monitoring		‡	‡	‡	‡	‡	‡	‡	‡	‡	‡
Final compliance assessment											†

*Visit 9: 1–3 days after visit 8.
†Both integrative group and conventional group.
‡Integrative group.
FVC, frequency–volume chart; IPSS, International Prostate Symptom Score; SF-36, Short-Form 36-Question Health Survey; PGIC, patient’s global impression of changes; PSA, prostate-specific antigen; PVR, post-void residual urine volume; Qmax, maximum urinary flow rate; TRUS, transrectal ultrasonography.